• Livzon unit Shanghai Livzon secured NMPA clearance to market leuprorelin acetate microspheres injection 11.25 mg, a three-month formulation.
• Greenlight adds an 11.25 mg specification to the product line, supplementing existing 3.75 mg and 1.88 mg versions.
• R&D spending on the three-month formulation totaled about RMB 94.0548 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livzon Pharmaceutical Group Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260929-12351046), on September 29, 2026, and is solely responsible for the information contained therein.